Andrew Francis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Francis has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Georgios Petrides
2 shared publicationsAdeeb Yacoub
Department of Psychiatry and Behavioral Science, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA
1 shared publicationAksel Bertelsen
1 shared publicationAndrea Eugenio Cavanna
1 shared publicationBrendan T. Carroll
1 shared publicationDavid Cohen
1 shared publication
Latest Publications
- 1 November 2014
- Published by Elsevier in Psychosomatics
- Vol. 55 (6) , 703-707
Two Cases of Catatonia With Thyroid Dysfunction
- 1 November 2014
- Published by Elsevier in Psychosomatics
- Vol. 55 (6) , 703-707
Two Cases of Catatonia With Thyroid Dysfunction
- 1 December 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (4) , 246-247
Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
- 1 December 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (4) , 246-247
Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
- 14 April 2010
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 12 (3) , 180-185
Catatonia: Diagnosis, Classification, and Treatment
Catatonia is a distinct neuropsychiatric syndrome that is becoming more recognized clinically and in ongoing research. It occurs with psychiatric, metabolic, or neurologic conditions. It may occur in many forms, including neuroleptic malignant syndrome. Treatment with benzodiazepines or electroconvulsive therapy leads to a dramatic and rapid response, although systematic, randomized trials are lacking. An important unresolved question is the role of antipsychotic agents in treatment and their potential adverse effects.
- 14 April 2010
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 12 (3) , 180-185
Catatonia: Diagnosis, Classification, and Treatment
Catatonia is a distinct neuropsychiatric syndrome that is becoming more recognized clinically and in ongoing research. It occurs with psychiatric, metabolic, or neurologic conditions. It may occur in many forms, including neuroleptic malignant syndrome. Treatment with benzodiazepines or electroconvulsive therapy leads to a dramatic and rapid response, although systematic, randomized trials are lacking. An important unresolved question is the role of antipsychotic agents in treatment and their potential adverse effects.
- Open Access
- 12 March 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 9
Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study
Objective: The objective of this study was to compare intramuscular (IM) ziprasidone to conventional IM medications (haloperidol combined with lorazepam) for the treatment of severe agitation in adolescents (age 12–17). Methods: We retrospectively identified consecutive severe agitation episodes (defined as requiring physical restraint) in adolescents treated with either IM ziprasidone or conventional IM agents in a psychiatric emergency room. For ziprasidone, the dosage was 20 mg for 23 episodes and 10 mg for 5 episodes. For 24 episodes treated with combined haloperidol and lorazepam, the dosages were 4.8 ± 0.3 SEM mg and 1.9 ± 0.4 mg respectively. Outcomes were the duration of restraint and need for adjunctive "rescue" medications within 60 minutes. These outcomes were decided prior to reviewing any records. Results: No difference was found in restraint duration (ziprasidone, N = 28, 55 ± 5 minutes; haloperidol with lorazepam N = 24, 65 ± 7 minutes, P = NS). Use of "rescue" medications did not differ between the two groups. No changes in blood pressure were found, but pulse decreased 8.3 ± 2.4 for haloperidol with lorazepam and 8.9 ± 4.24 for ziprasidone (P = NS). No instances of excessive sedation or extra-pyramidal symptoms were documented. Conclusion: In this study, IM ziprasidone appeared effective, well tolerated, and similar in clinical profile to combined conventional IM medications for treating severe agitation in adolescents. Given the reportedly favorable acute side effect profile of parenteral atypical agents, they may provide an alternative to conventional antipsychotics for treating acute agitation in both adult and adolescent populations. Future randomized, controlled studies are needed.
- 12 March 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 9
Open AccessConventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study
Objective: The objective of this study was to compare intramuscular (IM) ziprasidone to conventional IM medications (haloperidol combined with lorazepam) for the treatment of severe agitation in adolescents (age 12–17). Methods: We retrospectively identified consecutive severe agitation episodes (defined as requiring physical restraint) in adolescents treated with either IM ziprasidone or conventional IM agents in a psychiatric emergency room. For ziprasidone, the dosage was 20 mg for 23 episodes and 10 mg for 5 episodes. For 24 episodes treated with combined haloperidol and lorazepam, the dosages were 4.8 ± 0.3 SEM mg and 1.9 ± 0.4 mg respectively. Outcomes were the duration of restraint and need for adjunctive "rescue" medications within 60 minutes. These outcomes were decided prior to reviewing any records. Results: No difference was found in restraint duration (ziprasidone, N = 28, 55 ± 5 minutes; haloperidol with lorazepam N = 24, 65 ± 7 minutes, P = NS). Use of "rescue" medications did not differ between the two groups. No changes in blood pressure were found, but pulse decreased 8.3 ± 2.4 for haloperidol with lorazepam and 8.9 ± 4.24 for ziprasidone (P = NS). No instances of excessive sedation or extra-pyramidal symptoms were documented. Conclusion: In this study, IM ziprasidone appeared effective, well tolerated, and similar in clinical profile to combined conventional IM medications for treating severe agitation in adolescents. Given the reportedly favorable acute side effect profile of parenteral atypical agents, they may provide an alternative to conventional antipsychotics for treating acute agitation in both adult and adolescent populations. Future randomized, controlled studies are needed.
- Open Access
- 1 January 2006
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 2 (2) , 235-240
Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam
The authors report three cases of neuroleptic malignant syndrome (NMS) induced by atypical antipsychotics (olanzapine and clozapine) which showed classic features of NMS including muscular rigidity and prominent fever. Case reports. A 66-year-old man with dementia and alcohol abuse developed NMS while on olanzapine for agitation and combativeness. A 62-year-old man with schizophrenia developed NMS 6 days after starting clozapine. A 43-year-old man with bipolar disorder developed NMS 14 days after starting clozapine. All three cases showed classic features of NMS including muscular rigidity and fever. Resolution of fever and muscular rigidity occurred within 72 hours with discontinuation of neuroleptics, supportive care, and lorazepam. The NMS rating scale reflected daily clinical improvement. Classic NMS characterized by muscular rigidity and prominent fever may occur with atypical neuroleptics. Our cases suggest recovery from NMS associated with atypical neuroleptics may be hastened by lorazepam, as was previously reported for NMS from typical neuroleptics. Also, the NMS rating scale was sensitive to clinical improvement.
- 1 January 2006
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 2 (2) , 235-240
Open AccessNeuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam
The authors report three cases of neuroleptic malignant syndrome (NMS) induced by atypical antipsychotics (olanzapine and clozapine) which showed classic features of NMS including muscular rigidity and prominent fever. Case reports. A 66-year-old man with dementia and alcohol abuse developed NMS while on olanzapine for agitation and combativeness. A 62-year-old man with schizophrenia developed NMS 6 days after starting clozapine. A 43-year-old man with bipolar disorder developed NMS 14 days after starting clozapine. All three cases showed classic features of NMS including muscular rigidity and fever. Resolution of fever and muscular rigidity occurred within 72 hours with discontinuation of neuroleptics, supportive care, and lorazepam. The NMS rating scale reflected daily clinical improvement. Classic NMS characterized by muscular rigidity and prominent fever may occur with atypical neuroleptics. Our cases suggest recovery from NMS associated with atypical neuroleptics may be hastened by lorazepam, as was previously reported for NMS from typical neuroleptics. Also, the NMS rating scale was sensitive to clinical improvement.
- 17 October 1997
- Published by Elsevier in Schizophrenia Research
- Vol. 27 (1) , 83-92
Catatonia and other motor syndromes in a chronically hospitalized psychiatric population
- 17 October 1997
- Published by Elsevier in Schizophrenia Research
- Vol. 27 (1) , 83-92
Catatonia and other motor syndromes in a chronically hospitalized psychiatric population
- 20 May 1996
- Published by Elsevier in Brain Research
- Vol. 721 (1-2) , 150-154
Genetic variation in immediate and delayed postictal refractory period in rats
- 20 May 1996
- Published by Elsevier in Brain Research
- Vol. 721 (1-2) , 150-154
Genetic variation in immediate and delayed postictal refractory period in rats